Anika Therapeutics, Inc. Sustainability Profile
Anika Therapeutics, Inc., a leading player in the biotechnology industry, is headquartered in the United States and focuses on developing innovative therapies for musculoskeletal health. Founded in 1983, Anika has achieved significant milestones, including the introduction of its proprietary hyaluronic acid-based products, which are designed to enhance joint health and improve patient outcomes. The company’s core offerings include viscosupplementation treatments and regenerative medicine solutions, setting it apart through its commitment to scientific excellence and patient-centric approaches. Anika Therapeutics has established a strong market position, recognised for its contributions to orthopaedics and sports medicine, and continues to expand its operational reach across major regions in North America and Europe. With a robust pipeline of products, Anika remains dedicated to advancing the field of therapeutic solutions for joint health.
DitchCarbon Score
How does Anika Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Anika Therapeutics, Inc.'s score of 26 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Anika Therapeutics, Inc.'s reported carbon emissions
Anika Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi). As there is no available data on emissions or reduction initiatives, it is unclear how Anika Therapeutics is addressing climate change within its operations. The lack of reported emissions and climate commitments may reflect a broader industry context where many companies are still developing their sustainability strategies. In summary, Anika Therapeutics, Inc. has not disclosed any carbon emissions data or climate commitments, leaving a gap in understanding its environmental impact and sustainability efforts.
How Carbon Intensive is Anika Therapeutics, Inc.'s Industry?
How Carbon Intensive is Anika Therapeutics, Inc.'s Location?
Anika Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Anika Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
